Bernard Nicholson’s Pulse Colon is a device and protocol that seeks to detect early colon changes by measuring electrical and pressure signals. The team behind it released clinical notes in 2024 and updated protocols in 2025. The product claims to offer a faster screening path than some standard tests. This guide explains the origin, method, and safety in clear terms.
Key Takeaways
- Bernard Nicholson’s Pulse Colon uses electrical and pressure signals to detect early colon changes, offering a faster screening adjunct to traditional colonoscopy.
- The device measures local electrical conductance and pressure waveforms to identify abnormal tissue potentially linked to polyps or lesions.
- Current evidence shows moderate sensitivity but requires larger, independent trials before widespread clinical adoption.
- Safety protocols include low-voltage pulses, biocompatible probes, sedation, and bowel prep, with adverse events reported as rare and mild.
- Clinicians should use the Pulse Colon as an investigational tool alongside established screening methods and participate in outcome tracking and trials.
- Patients should discuss the device’s trial status with providers and prioritize standard colonoscopy when at high colorectal cancer risk.
What Bernard Nicholson’s Pulse Colon Claims To Be And Its Origins
Bernard Nicholson’s Pulse Colon started as a research idea in a small clinical lab. The inventor, Bernard Nicholson, proposed using timed electrical pulses and pressure sensors to read colon responses. The device combines a flexible probe, a pulse generator, and software that logs signal patterns. The initial papers appeared in 2024 and showed pilot data from 72 patients.
The team marketed the method as a screening adjunct rather than a diagnostic replacement. They wrote that the device can highlight areas that warrant colonoscopy or imaging. The developers said the method aims to reduce wait times for patients who face limited endoscopy access.
Independent groups replicated parts of the technique in 2025. Those groups focused on signal consistency and software algorithms. They reported mixed results: some studies found clear signal differences in patients with polyps, while others found weak correlations with lesion size. Regulators in several countries reviewed the device documentation. Some regulators granted limited-use approvals for research settings. Other regulators requested further clinical trials.
Clinical teams and hospitals considering the device should note the claims versus evidence gap. The company claims high sensitivity in early reports. Peer reviewers asked for larger, multicenter trials. Clinicians should treat the method as an investigational tool until consistent, independent data appear. Bernard Nicholson’s Pulse Colon continues to collect trial data and to refine its algorithms.
How The Pulse Colon Works, Key Mechanisms, And Safety Considerations
The Pulse Colon records two main signals: electrical activity and pressure changes along the colon. The device sends small electrical pulses and records the tissue response. It measures the timing and amplitude of pressure waves as the probe moves. Software converts those raw signals into pattern maps. Clinicians read the maps to find abnormal zones that might match lesions or motility changes.
The method assumes that abnormal tissue alters local electrical conductance and mechanical response. Benign polyps and malignant lesions can change local conductivity. Inflammation can change pressure waveforms. The system uses machine learning classifiers trained on labeled examples to flag suspicious patterns. Those classifiers use signal features such as peak amplitude, recovery time, and local variance.
Safety reviews emphasize several points. First, the pulses use low voltage and short duration. Engineers designed the pulses to stay well below cardiac stimulation thresholds. Second, the probe uses biocompatible materials and standard sterilization. Third, clinicians should use sedation and standard bowel prep similar to endoscopy to limit risk.
Reported adverse events in trials were rare. Trials logged mild discomfort, transient cramping, and one device-related mucosal abrasion among 300 procedures. No device-related perforations occurred in published series. Still, larger studies are necessary to establish the true safety profile. Clinicians must follow device protocols and stop the procedure if resistance or pain rises.
Device teams recommend structured training. Operators should learn probe handling, signal troubleshooting, and pattern interpretation. The software gives confidence scores, but clinicians must confirm flagged zones with standard diagnostic tools. Hospitals should track outcomes and report device-related events to registries. Those steps will help validate safety and practical use of Bernard Nicholson’s Pulse Colon.
Evidence, Alternatives, And Practical Next Steps For Patients And Clinicians
The evidence base for Bernard Nicholson’s Pulse Colon remains limited but growing. Two single-center trials reported sensitivity between 65% and 78% for lesions larger than 6 mm. A pooled analysis of early reports showed high negative predictive value in low-risk groups. But, reviewers noted selection bias and small sample sizes.
Clinicians can consider alternatives. Standard colonoscopy remains the gold standard for diagnosis and removal of lesions. CT colonography provides a noninvasive option with strong detection for larger polyps. Stool-based tests such as FIT and DNA tests offer population screening with low procedural risk. Each option carries trade-offs in sensitivity, cost, and access.
Practical steps for clinicians who want to evaluate the Pulse Colon include joining approved trials, auditing outcomes, and comparing device findings to colonoscopy results. Clinicians should document lesion size, location, histology, and whether the device flagged the zone. That documentation will build clarity on performance across patient groups.
Practical steps for patients include asking whether the device sits under an approved trial and what follow-up tests will occur if the device flags an area. Patients should ask about alternative screening methods and about how clinicians will confirm any abnormal result. Patients with high risk for colorectal cancer should prioritize colonoscopy per guideline recommendations.
Overall, Bernard Nicholson’s Pulse Colon shows promise as a rapid screening adjunct. The method requires more independent validation. Clinicians and patients should treat it as an investigational option and maintain standard diagnostic pathways until stronger evidence appears.